CDMOs move from outsourced suppliers to strategic partners in tougher drug development market

The relationship between drug developers and contract development and manufacturing organisations has shifted markedly over the past decade. What was once often treated as a straightforward outsourcing arrangement is increasingly viewed as a strategic alliance, with sponsors looking for partners who can do more than simply follow instructions. In a sector shaped by tighter margins, regulatory pressure and growing technical complexity, the most valued CDMOs are now expected to bring ju...

Jeff Mocny, vice president for scientific leadership at Rose BioSolutions, told BioSpace that the best partnerships are built on shared purpose rather than a narrow service agreement. As programmes advance, he said, the needs of the sponsor may change, but the underlying expectations of trust, reliability and scientific rigour should not. In his view, the CDMO’s role is to help shield clients from avoidable risk while remaining aligned to the ultimate goal: moving a product successfully through development and into supply.

That broader definition of value has become more important as the industry has wrestled with inflationary pressure, supply chain strain and a more demanding regulatory environment. Rising costs for raw materials and transport have squeezed margins, while pharmaceutical companies have limited room to pass those costs on. At the same time, companies are paying closer attention to manufacturing resilience, including nearshoring and the diversification of production sites to reduce exposure to geopolitical shocks. On the regulatory front, BioSpace reported that FDA inspection activity increased sharply in 2025, with untitled letters and Form 483 observations both rising, underlining the importance of strong compliance planning from the earliest stages of development.

Against that backdrop, CDMOs are being asked to contribute more than operational execution. Sponsors increasingly want partners who can provide rapid data, specialised expertise and a clear understanding of the development landscape. Mocny argued that this begins with a precise definition of the product and the pathway it is meant to follow. Without that clarity, he said, it becomes far harder to spot where the risks are likely to emerge, or to determine whether the selected regulatory strategy is actually fit for purpose.

He also emphasised that strategy and execution are distinct disciplines, even if they must work closely together. A development plan may point in one direction, but day-to-day execution reveals whether that direction is realistic. In practical terms, that means the CDMO should be willing to test assumptions, ask awkward questions and identify weaknesses before they become costly mistakes. Mocny described the best collaborator as one that is “politely critical”, inquisitive and thoughtful, rather than passive.

That approach is particularly important in complex programmes where the product does not fit neatly into a single regulatory or manufacturing category. In such cases, each component of the composition may need to be considered separately and then as part of the whole. Sponsors, Mocny suggested, often underestimate how much compliance work is involved in making those judgements. The strongest CDMO partners can bridge the gap between scientific rationale and regulatory expectations, helping clients interpret guidance and defend their choices with confidence.

Clear communication sits at the centre of that process. Mocny said trust grows when information is shared openly and when both sides feel able to challenge each other constructively. That theme is echoed across the outsourcing sector. Allison Vavala, senior director of business development at Flamma, has said that transparency and early problem-solving are often what determine whether a programme stays on track. The message from both executives is similar: technical skill matters, but relationships fail or succeed on the quality of the dialogue between sponsor and provider.

The market is increasingly rewarding that more integrated model. Recent partnership announcements across the sector show CDMOs and their collaborators moving beyond transactional work towards more tightly connected development platforms. Matica BioLabs and DT&CRO, for instance, have announced a tie-up intended to join manufacturing with preclinical and clinical development, with the aim of shortening timelines and improving the chances of success. Abzena and Argonaut Manufacturing Services have also unveiled a collaboration designed to offer a more seamless route from early discovery to clinical and commercial manufacturing, while LOTTE BIOLOGICS and SK pharmteco have said they intend to combine capabilities in the fast-growing antibody-drug conjugate market. Elsewhere, Protheragen and Zencore Biologics are seeking to connect global client networks with biologics manufacturing capacity in a model meant to support Chinese innovation projects going international.

Taken together, those alliances point to a wider industry shift. Sponsors no longer seem satisfied with partners who simply deliver a specified task to a fixed brief. They are looking for organisations that can anticipate manufacturing hurdles, question weak assumptions and help shape development strategy from the outset. For CDMOs, that means the competitive advantage increasingly lies in insight and honesty as much as in infrastructure. In Mocny’s view, and in the direction the industry appears to be moving, the most successful partnerships will be those in which both sides understand that good service sometimes means saying no, slowing down, or challenging the plan before it goes wrong.

Source: Noah Wire Services